FCGR3A and cancer: For most cancers, only a subset of patients exhibit durable anti-tumour responses following immunotherapy and relapse remains a significant problem for haematological malignancies following HCST [54,119] and so strategies to exploit favourable donor immunogenetics are also warranted (e.g., KIR/HLA as well as CD16 genotypes).